Actively Recruiting
Phase 2 Study of JS207 Combination Therapies for Adults with Advanced Driver Gene-Positive Non-Small Cell Lung Cancer After TKI Treatment Failure
Led by Shanghai Junshi Bioscience Co., Ltd. · Updated on 2026-05-18
78
Participants Needed
1
Research Sites
82 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating treatments for patients with advanced non-squamous non-small cell lung cancer NSCLC who have specific positive driver gene mutations and have not responded to tyrosine kinase inhibitor TKI therapy. This phase II clinical trial aims to assess the safety, tolerability, and early effectiveness of combination therapies involving JS207, a PD-1VEGF bispecific antibody, with other drugs in this patient group. The study plans to enroll approximately 66 to 78 participants. Participants are divided into two groups Cohort 1 receives JS207 10 or 15 mgkg intravenously on day 1 combined with pemetrexed 500 mgm IV on day 1 and platinum-based chemotherapy carboplatin or cisplatin every three weeks for four cycles. After these cycles, JS207 and pemetrexed continue every three weeks as maintenance until stopping criteria are met. Cohort 2 receives JS207 10 mgkg IV on day 1 combined with JS212 4.2 mgkg or another selected dose IV on day 1 every three weeks until treatment ends. Participants will undergo regular assessments including evaluations of tumor response, survival, and side effects for up to about 37 months. Researchers will measure objective response rates and other outcomes like progression-free survival and overall survival. Safety and lab tests will also be monitored throughout the study period, with ongoing follow-up to track the effects and tolerability of the treatments.
CONDITIONS
Brief Title
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
Research Team
M
Mei Yue, Master
H
Huiyu Lan, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here